Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06100263 · ClinicalTrials.gov registry record · NA

Breast Cancer Resiliency Through Exercise Program (B-REP)

A NA study of Breast Cancer Female, sponsored by University of Michigan Rogel Cancer Center.

Recruiting
Registry status
NA
Development phase
75
Enrollment target
1
Study location

NCT06100263: Recruiting NA study of Breast Cancer Female, sponsored by University of Michigan Rogel Cancer Center.

NCT06100263 is a NA study of Breast Cancer Female that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 75 participants, below the 691-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06100263, a NA study of Breast Cancer Female, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.

RECRUITING
Registry status
NA
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The study will use a cross-sectional study design with a follow-up 2-arm randomized controlled trial with that has assessments at baseline, post-intervention (i.e., Week 12), and 3-months post-intervention (i.e., Week 24). The 2 arms are the 12-week intervention and waitlist control among 30 Black breast cancer survivors

Primary Outcome

Percent of patients that complete the intervention

Conditions Studied

Interventions

  • OTHER Individualized exercise program
  • OTHER Control Arm

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2024-05-28
Est. Completion 2026-12
Phase NA

What NCT06100263 shows while recruiting

NCT06100263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 691-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 2 interventions - of which Individualized exercise program is the first listed.

NCT06100263 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT06100263 about?

NCT06100263 is a clinical study titled "Breast Cancer Resiliency Through Exercise Program (B-REP)". The study will use a cross-sectional study design with a follow-up 2-arm randomized controlled trial with that has assessments at baseline, post-intervention (i.e., Week 12), and 3-months post-intervention (i.e., Week 24). The 2 arms are the 12-week intervention and waitlist control among 30 Black b...

What is the current status of trial NCT06100263?

This trial is currently recruiting. It is a NA study. The enrollment target is 75 participants. The study started on 2024-05-28. Estimated completion is 2026-12.

What conditions does trial NCT06100263 study?

This clinical trial studies the following conditions: Breast Cancer Female.

What interventions are being tested in trial NCT06100263?

The interventions under investigation include: Individualized exercise program (OTHER), Control Arm (OTHER).

Who is sponsoring clinical trial NCT06100263?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06100263 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer Female

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06100263's enrollment target sits among peer trials

75 28th of 46 higher than 19 of 46 other Breast Cancer Female trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06100263, the US trial registry maintained by the National Library of Medicine. NCT06100263 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.